Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Efficacy of tolvaptan in patients with refractory ascites in a clinical setting
Takamasa Ohki, Koki Sato, Tomoharu Yamada, Mari Yamagami, Daisaku Ito, Koki Kawanishi, Kentaro Kojima, Michiharu Seki, Nobuo Toda, Kazumi Tagawa, Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan
Author contributions: All authors contributed to this paper.
Ethics approval: This is a retrospective study. We have no statement about institutional review board.
Informed consent: For this type of retrospective study formal consent is not required.
Conflict-of-interest: We have no conflict of interests.
Data sharing: Technical appendix, statistical code, and dataset available from the corresponding author at following e-mail address (anb72547@nifty.com). Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Takamasa Ohki, MD, PhD, Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, Chiyoda-ku, Tokyo 101-8643, Japan. anb72547@nifty.com
Telephone: +81-3-38629111
Received: March 5, 2015
Peer-review started: March 6, 2015
First decision: April 17, 2015
Revised: May 11, 2015
Accepted: June 9, 2015
Article in press: June 11, 2015
Published online: June 28, 2015
Processing time: 115 Days and 23.1 Hours
Peer-review started: March 6, 2015
First decision: April 17, 2015
Revised: May 11, 2015
Accepted: June 9, 2015
Article in press: June 11, 2015
Published online: June 28, 2015
Processing time: 115 Days and 23.1 Hours
Core Tip
Core tip: Tolvaptan (TLV) was effective in 38 (63.3%) refractory ascites patients. The best cut-off values for urine output and reduced urine osmolality as measures of refractory ascites improvement were > 1800 mL within the first 24 h and > 30%, respectively. The cumulative incidence rate was significantly higher in the control group with a median incidence time of 30 d in the TLV group and 20 d in the control group. Administration of TLV results in better control of refractory ascites and reduced the incidence of additional invasive procedures or hospitalization compared with conventional ascites treatments.